Investigators from Beihang University Zero in on Acute Colitis (Oral-administered Allomelanin-like Nanomedicine With Multi-enzyme Mimesis and Favorable Gastrointestinal Tolerance for Amelioration of Acute Colitis).
In: Drug Week, 2024-05-24, S. 960
serialPeriodical
Zugriff:
A recent study conducted by researchers at Beihang University in Beijing, China, has focused on the development of a nanomedicine for the treatment of acute colitis. The researchers created a biocompatible nanomedicine called alloMel, which demonstrated favorable tolerance in the gastrointestinal tract and showed promising therapeutic efficacy in mice with acute colitis. AlloMel was found to alleviate oxidative stress, reduce inflammation, restore intestinal barrier integrity, and inhibit the TLR4/MyD88/NF-κB signaling pathway. This research suggests that alloMel could be a potential nanomedicine for the treatment of colitis and other gastrointestinal inflammatory disorders associated with oxidative stress. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Investigators from Beihang University Zero in on Acute Colitis (Oral-administered Allomelanin-like Nanomedicine With Multi-enzyme Mimesis and Favorable Gastrointestinal Tolerance for Amelioration of Acute Colitis).
|
---|---|
Zeitschrift: | Drug Week, 2024-05-24, S. 960 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|